Chugai Pharmaceutical Co., Ltd. (CHGCF)

Market Cap	70.72B -5.4%
Revenue (ttm)	9.00B +16.5%
Net Income	3.21B +26.8%
EPS	1.93 +26.8%
Shares Out	n/a
PE Ratio	22.60
Forward PE	n/a
Dividend	0.82 (1.89%)
Ex-Dividend Date	Dec 29, 2026

Volume	449
Open	42.63
Previous Close	45.13
Day's Range	42.63 - 43.73
52-Week Range	34.79 - 68.08
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,104
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCF

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error